GL 331

02/01/2000 - "These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents."
01/01/2017 - "Moreover, the cytotoxicity of XWL-1-48 is more potent than its congener GL331 and the IC50 values are from 0.34 ± 0.21 to 3.54 ± 0.54 µM in 10 cancer cell lines including KBV200 cells with P-gp overexpression. "
02/28/2003 - "Therefore, our data showed that GL331 is a potent inhibitor of tumor-induced angiogenesis. "
02/28/2003 - "We have studied GL331's anti-cancer mechanisms by studying their effect on the tumor-induced angiogenesis. "
02/01/2000 - "In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents."

02/01/2000 - "In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. "
03/01/2001 - "In this study, we intended to evaluate the efficacy of combining GL331 with paclitaxel in cell killing and apoptotic induction in nasopharyngeal carcinoma NPC-TW01 cells. "
07/15/1997 - "In this study, we found that the CDC 2 kinase could be transiently activated when nasopharyngeal carcinoma NPC-TW01 cells were treated for 3 h with a new anticancer agent, GL331. "

05/01/2006 - "The glioma cells were treated with GL331 and the clonogenic assay was used to study its cytotoxicity effects. "
05/01/2006 - "The induction of GL331 radiosensitization was sequence-dependent, with stronger cytotoxic effects on the gliomas noted where radiation was delivered concomitantly with the beginning of GL331 treatment. "
05/01/2006 - "FACS analysis revealed that GL331 and radiation caused the glioma cells to accumulate in the G2/M-phase of the cell cycle and combination of these two treatments as the RT-GL331 protocol further increased the G2/M fraction of the glioma cells. "
05/01/2006 - "The clonogenic assay demonstrated that GL331 exerts cytotoxic effects on the glioma cells in a concentration- and time-dependent manner (p < 0.001). "
11/01/2005 - "GL331 exerts cytotoxic effects and induces apoptosis in C6 glioma cells, accompanied by cell accumulation in the G2/M-phase and activation of p53, p21 and 14-3-3sigma."

10/01/2001 - "In this study, GL331 induced human lung adenocarcinoma cell line CL1-5 growth arrest before death during the initial 24-h incubation period. "
02/28/2003 - "Human lung adenocarcinoma CL1-5 cells were treated with GL331 and then maintained in serum-reduced, GL331-free medium for the preparation of condition mediums. "

05/01/2002 - "A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. "
05/01/2002 - "Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients."